Organization
IU Simon Comprehensive Cancer Center
6 abstracts
Abstract
Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.Org: Roswell Park Comprehensive Cancer Center, IU Simon Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center,
Abstract
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, IU Simon Comprehensive Cancer Center, Indianapolis, IN, Innovative Immunotherapy Alliance,
Abstract
Rates of colorectal cancer screening versus lung cancer screening: Where does the problem lie?Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center,
Abstract
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Indiana University Simon Cancer Center and Roudebush VAMC, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Melvin and Bren Simon Cancer Center, Indianapolis, IN,
Abstract
A randomized, open-label, phase II study of high-dose interleukin 2 vs high-dose interleukin 2 plus entinostat in renal cell carcinoma.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, USC Norris Comprehensive Cancer Center, Keck Medicine of USC, Nebraska Cancer Specialists - Midwest Cancer Center, Rush University Medical Center,
Abstract
Patient perception and adherence to lung cancer screening in those who meet eligibility criteria.Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center,